<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03942419</url>
  </required_header>
  <id_info>
    <org_study_id>EYN-MYO-AT-31</org_study_id>
    <nct_id>NCT03942419</nct_id>
  </id_info>
  <brief_title>Microdosed Atropine 0.1% and 0.01% Ophthalmic Solutions for Reduction of Pediatric Myopia Progression</brief_title>
  <official_title>A Multicenter, Double-Masked, Randomized, Placebo-Controlled Phase 3 Study of the Safety and Efficacy of Atropine 0.1% and 0.01% Ophthalmic Solutions Administered With a Microdose Dispenser for the Reduction of Pediatric Myopia Progression (The CHAPERONE Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eyenovia Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eyenovia Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the progression of myopia in participants using microdosed atropine
      0.01%, atropine 0.1%, or placebo ophthalmic solution. Eligible subjects will administer study
      medication daily in each eye for 48 months. Efficacy and safety assessments will be performed
      at visits scheduled for 1, 6, 12, 18, 24, 30 and 36 months after initiation of medication
      use. Subjects will be re-randomized at the 36 month visit, then followed at 6 month intervals
      for an additional year.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be evaluated for eligibility during an initial Screening Visit and enrolled
      after signing the study-specific informed consent form(s). Eligible subjects must complete a
      run-in period where they use the microdose dispenser to administer study drug &quot;vehicle&quot;
      solution daily in both eyes. After run-in, subjects return for a Baseline Visit and
      additional study eligibility assessments. Subjects who continue to be eligible will be
      equally randomized to one of the following treatment groups:

        -  Microdose atropine 0.1% ophthalmic solution

        -  Microdose atropine 0.01% ophthalmic solution

        -  Microdose placebo ophthalmic solution

      Randomization will be stratified by iris color (e.g., dark and light) and study site. Study
      enrollment will be limited to a maximum of 50% of subjects who self-identify as East Asian
      ethnicity. Subjects will use their assigned study medication daily in both eyes and return
      for efficacy and safety assessments at 1, 6, 12, 18, 24, 30, and 36 months.

      At the Month 36 Visit, subjects in the 2 atropine dose arms will be re-randomized to either
      placebo or 1 of the 2 doses of atropine ophthalmic solution, while subjects originally
      assigned to placebo will be re-randomized to one of the 2 atropine ophthalmic solution arms.
      After re-randomization, all subjects will be followed for an additional year with efficacy
      and safety examinations at Months 42 and 48.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 3, 2019</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a multi-center, double masked, randomized, placebo-controlled study evaluating the efficacy of microdosed atropine 0.01%, atropine 0.1% and placebo ophthalmic solutions. Subjects will administer their assigned medication daily in both eyes for 36 months, then be re-randomized to the same or an alternative treatment arm and followed for an additional 12 months.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>There will be no differences in the presentation of study drug administered. All study personnel conducting ophthalmic assessments will be masked to treatment assignment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Myopia progression</measure>
    <time_frame>36 Months</time_frame>
    <description>The proportion of primary study eyes showing less than 0.50 D (spherical equivalent) myopia progression compared to baseline measured using cycloplegic autorefraction.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">420</enrollment>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>Atropine 0.1% Ophthalmic Solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atropine 0.1% ophthalmic solution administered daily in both eyes using a microdose dispenser</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atropine 0.01% Ophthalmic Solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atropine 0.01% ophthalmic solution administered daily in both eyes using a microdose dispenser</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Ophthalmic Solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo ophthalmic solution administered daily in both eyes using a microdose dispenser</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atropine 0.1% Ophthalmic Solution</intervention_name>
    <description>Atropine 0.1% ophthalmic solution administered with a microdose dispenser</description>
    <arm_group_label>Atropine 0.1% Ophthalmic Solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atropine 0.01% Ophthalmic Solution</intervention_name>
    <description>Atropine 0.01% ophthalmic solution administered with a microdose dispenser</description>
    <arm_group_label>Atropine 0.01% Ophthalmic Solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Ophthalmic Solution</intervention_name>
    <description>Placebo ophthalmic solution administered with a microdose dispenser</description>
    <arm_group_label>Placebo Ophthalmic Solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Refractive error by cycloplegic autorefraction: myopia -1.00 D to -6.00 D in both
             eyes; astigmatism ≤ 1.50 D in both eyes; anisometropia &lt; 1.50 D.

          -  Best-corrected distance visual acuity in current correction of 0.2 logMAR or better
             with interocular difference ≤ 0.1 logMAR.

          -  Refractive correction for each eye meets the following criteria: myopia within ± 0.50
             D of the manifest refraction at the Screening Visit; cylinder power within ± 0.50 D of
             the manifest refraction at the Screening Visit; when cylinder power is &lt; 1.00 D, axis
             within ± 15 degrees of the manifest refraction; when cylinder power is ≥ 1.00 D, axis
             within ± 5 degrees of the manifest refraction.

        Exclusion Criteria:

          -  Current or previous myopia treatment with non-study atropine, pirenzepine or other
             topical anti-muscarinic agent.

          -  Current use of bifocals, progressive-addition lenses, or multifocal soft contact
             lenses.

          -  Use of rigid gas permeable lenses, including orthokeratology lenses within 90 days of
             Screening.

          -  Known atropine allergy.

          -  Abnormality of the cornea, lens, central retina, iris or ciliary body.

          -  Current or prior history of manifest strabismus, amblyopia, or nystagmus.

          -  Prior eyelid, strabismus, intraocular, or refractive surgery.

          -  Intraocular pressure &gt; 26 mmHg.

          -  History of premature birth by parent's report.

          -  Inability to perform protocol-prescribed testing due to preexisting neurological
             diagnoses, genetic syndrome, or other issues.

          -  Medical conditions predisposing patient to degenerative myopia, abnormal ocular
             refractive anatomy, and/or any history of intraocular surgery.

          -  Any systemic disease or condition that may affect visual function or development such
             as diabetes mellitus.

          -  Any ocular inflammation or external ocular inflammation within 30 days of Screening.

          -  History of punctal occlusion.

          -  Heterochromia.

          -  Lid squeezers.

          -  Participation in any study of an investigational, interventional product within 30
             days prior to Screening Visit.

          -  Immediate family member of study staff designed to perform study evaluations or
             procedures.

          -  Pregnancy, or if sexually active, unwillingness to use an acceptable form of
             contraception during the study.

          -  Presence of a severe/serious ocular condition or any other unstable medical condition
             that, in the Investigator's opinion, may preclude study treatment or follow-up.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tsontcho Ianchulev, MD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Eyenovia Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Greg M Bennett, MSEd</last_name>
    <phone>650-504-2005</phone>
    <email>gbennett@eyenoviabio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ginger Clasby, MS</last_name>
    <phone>714-269-8838</phone>
    <email>gclasby@eyenoviabio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Midwestern University</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracy Bland</last_name>
      <phone>623-806-7246</phone>
      <email>tbland@midwestern.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Canyon City Eyecare</name>
      <address>
        <city>Azusa</city>
        <state>California</state>
        <zip>91702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debbie Beltran</last_name>
      <phone>626-963-7100</phone>
      <email>angelbeltran06@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marshall Ketchum University College of Optometry</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Parker</last_name>
      <email>sparker@ketchum.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ratner Children's Eye Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erika Castro</last_name>
      <phone>858-822-1347</phone>
      <email>efcastro@ucsd.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Illinois College of Optometry</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60616</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elyse Nylin</last_name>
      <phone>312-949-7298</phone>
      <email>enylin@ico.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Midwestern University</name>
      <address>
        <city>Downers Grove</city>
        <state>Illinois</state>
        <zip>60515</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katarina Ivkovic</last_name>
      <phone>630-743-4844</phone>
      <email>kivkov@midwestern.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Michigan College of Optometry</name>
      <address>
        <city>Big Rapids</city>
        <state>Michigan</state>
        <zip>49307</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rhonda Atteberry</last_name>
      <phone>231-591-2180</phone>
      <email>rhondaatteberry@ferris.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>SUNY College of Optometry</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10036</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Bicomong</last_name>
      <email>mbicomong@sunyopt.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wake Forest Health Network Ophthalmology - Oak Hollow</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay Choe</last_name>
      <phone>336-802-2255</phone>
      <email>ychoe@wakehealth.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oculus Research</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Newsome</last_name>
      <phone>252-906-5415</phone>
      <email>jen.newsome.oculusresearch@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Ohio State University - College of Optometry</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Barger</last_name>
      <phone>614-292-8858</phone>
      <email>barger.120@osu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Scott &amp; Christie and Associates</name>
      <address>
        <city>Cranberry Township</city>
        <state>Pennsylvania</state>
        <zip>16066</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natasha Hindman, OD</last_name>
      <phone>724-772-5420</phone>
      <email>nhindman@scottandchristie.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Salus University - The Eye Institute</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jasmine Campbell</last_name>
      <phone>215-276-6021</phone>
      <email>jcampbell@salus.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Primary Eyecare Group</name>
      <address>
        <city>Brentwood</city>
        <state>Tennessee</state>
        <zip>37027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Emerton</last_name>
      <phone>615-373-0080</phone>
      <email>cemerton@primaryeyecare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saige Wilkins</last_name>
      <phone>615-936-1474</phone>
      <email>saige.wilkins@vumc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Pediatric Eye Center</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23452</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>April Rusch</last_name>
      <phone>757-471-3375</phone>
      <phone_ext>1</phone_ext>
      <email>tcrrusch@cox.net</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 7, 2019</study_first_submitted>
  <study_first_submitted_qc>May 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2019</study_first_posted>
  <last_update_submitted>June 19, 2020</last_update_submitted>
  <last_update_submitted_qc>June 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myopia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atropine</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

